chufangao/CTO huggingface dataset:
Clinical trial NCT01597778: Double Cord Versus Haploidentical (BMT CTN 1101)
Official title: A Multi-Center, Phase III, Randomized Trial of RIC and Transplantation of (dUCB) Versus HLA-Haplo Related Bone Marrow for Patients With Hematologic Malignancies.(BMT CTN #1101)
Sponsor: Medical College of Wisconsin (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 368.0 (ACTUAL)
Number of arms: 2.0
Start date: 2012-06-30
Primary completion date: 2020-09-11
Completion date: 2020-09-11
Baseline population: Baseline characteristics for all enrolled participants by treatment arm.
Plan to share individual participant data: YES
IPD sharing description: Results will be published in a manuscript and supporting information submitted to NIH BioLINCC (including data dictionaries, case report forms, data submission documentation, documentation for outcomes dataset, etc where indicated).
IPD time frame: Within 6 months of official study closure at participating sites.
IPD access criteria: Available to the public
Clinical trial NCT04003207: Growth Hormone Treatment in Children With Phelan McDermid Syndrome
Official title: An Open Label Trial of Growth Hormone in Children and Adolescents With Phelan-McDermid Syndrome Targeting Social Withdrawal
Sponsor: Icahn School of Medicine at Mount Sinai (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 6.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-09-13
Primary completion date: 2020-06-05
Completion date: 2020-06-05
Clinical trial NCT05406219: A Study to Learn How the Study Treatment BAY2395840 Moves Into, Through and Out of the Body, How Safe it is, and How it Affects the Body in Participants With Moderate Reduced Kidney Function and in Healthy Male and Female Participants With Normal Kidney Function
Official title: An Open-label, Single-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BAY 2395840 in Participants With Moderate Renal Impairment and in Healthy Male and Female Participants With Normal Renal Function
Sponsor: Bayer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Discontinuation of program.
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2023-05-15
Primary completion date: 2023-08-17
Completion date: 2023-10-12
Plan to share individual participant data: NO
IPD sharing description: Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA Principles for responsible clinical trial data sharing. This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014.~Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.
Clinical trial NCT03866317: A Study to Assess the Safety and Efficacy of Secukinumab in Alleviating Symptoms of Discoid Lupus Erythematosus
Official title: A Pilot Study to Assess the Safety and Efficacy of Secukinumab in Alleviating Symptoms of Discoid Lupus Erythematosus
Sponsor: Massachusetts General Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Difficulty recruiting participants
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-09-01
Primary completion date: 2021-06-30
Completion date: 2021-06-30
Plan to share individual participant data: UNDECIDED
Clinical trial NCT02818023: Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced Melanoma
Official title: Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib for Therapy of Advanced Melanoma
Sponsor: University of Pittsburgh (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Accrual to trial stopped due to high toxicity even at lowest dose of combination treatment. Patients on trial tolerating treatment at time of accrual closure still continued to receive treatment.
Enrollment: 9.0 (ACTUAL)
Number of arms: 1.0
Start date: 2016-07-13
Primary completion date: 2019-06-10
Completion date: 2021-04-23
Plan to share individual participant data: NO
Clinical trial NCT06022224: A 2nd Generation E1/E2B/E3-Deleted Adenoviral COVID-19 Vaccine: The TCELL VACCINE TRIAL
Official title: A Phase 2/3, Placebo-Controlled, Randomized, Observer-Blind Study To Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of a 2nd Generation E1/E2B/E3-Deleted Adenoviral COVID-19 Vaccine: The TCELL VACCINE TRIAL
Sponsor: ImmunityBio, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: TERMINATED 
Why stopped: There were no participants enrolled into Phase 3 portion of the study because the study was prematurely terminated.
Enrollment: 35.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-12-09
Primary completion date: 2022-06-23
Completion date: 2023-07-19
Limitations and caveats: There is an insufficient number of subjects enrolled to evaluate the efficacy of the Investigational Product. Thus, only safety results are provided.
Plan to share individual participant data: NO
Clinical trial NCT04421378: A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma
Official title: A Phase 1/2 Study of Selinexor in Combination With Standard of Care (SoC) Therapy for Newly Diagnosed or Recurrent Glioblastoma
Sponsor: Karyopharm Therapeutics Inc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Upon further consideration of the existing data and the competitive landscape, Karyopharm Therapeutics Inc has decided not to pursue the ongoing development of Selinexor in GBM at this time.
Enrollment: 74.0 (ACTUAL)
Number of arms: 8.0
Start date: 2020-06-08
Primary completion date: 2023-07-03
Completion date: 2023-07-03
Plan to share individual participant data: NO
Clinical trial NCT03074318: Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery
Official title: A Phase I/II Trial Combining Avelumab and Trabectedin for Advanced Liposarcoma and Leiomyosarcoma
Sponsor: Fred Hutchinson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Terminated due to PI leaving institution
Enrollment: 35.0 (ACTUAL)
Number of arms: 4.0
Start date: 2017-09-28
Primary completion date: 2020-11-15
Completion date: 2020-11-15
Plan to share individual participant data: NO
Clinical trial NCT04227275: A Study of CART-PSMA-TGFβRDN in Patients With Metastatic Castration Resistant Prostate Cancer
Official title: A Phase 1 Open-Label, Multi-Center Study of PSMA Targeted Genetically Modified Chimeric Antigen Receptor T Cells in Patients With Metastatic Castration Resistant Prostate Cancer
Sponsor: Tceleron Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Based on the safety events and evidence of biologic activity without sustained clinical responses the Sponsor finds the risk/benefit analysis unfavorable for patients and has terminated the study.
Enrollment: 16.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-11-22
Primary completion date: 2022-11-07
Completion date: 2022-11-07
Plan to share individual participant data: NO
Clinical trial NCT01778634: Trial of Intravenous Azithromycin to Eradicate Ureaplasma Respiratory Tract Infection in Preterm Infants
Official title: A Phase IIb Randomized, Placebo-controlled, Double-blind Trial of Azithromycin to Eradicate Ureaplasma Respiratory Tract Infection in Preterm Infants
Acronym: AZIPIII
Sponsor: University of Maryland, Baltimore (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 121.0 (ACTUAL)
Number of arms: 2.0
Start date: 2013-07-31
Primary completion date: 2016-12-31
Completion date: 2020-11-03
Clinical trial NCT04259346: A Study of Two Formulations of Ixekizumab in Healthy Participants
Official title: Bioequivalence of an Alternate Ixekizumab Formulation Compared to the Commercial Formulation in Healthy Subjects
Sponsor: Eli Lilly and Company (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 245.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-02-05
Primary completion date: 2021-02-19
Completion date: 2021-02-19
Baseline population: All randomized participants who received at least one dose of study drug.
Plan to share individual participant data: NO
Clinical trial NCT03802461: Effectiveness of Fecal Flora Alteration for Eradication of Carbapenemase-producing Enterobacteriaceae Colonization
Official title: Effectiveness of Fecal Flora Alteration for Eradication of Carbapenemase-producing Enterobacteriaceae Colonization Trial (EFFECT-CPE): a Multisite, Open-label, Randomized Controlled Feasibility Pilot Trial
Acronym: EFFECT-CPE
Sponsor: University Health Network, Toronto (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: SUSPENDED 
Why stopped: Temporarily on hold due to COVID-19 pandemic
Enrollment: 40.0 (ESTIMATED)
Number of arms: 2.0
Start date: 2019-03-22
Primary completion date: 2023-12-15
Completion date: 2024-03-20
Plan to share individual participant data: NO
Clinical trial NCT01164995: Study With Wee-1 Inhibitor AZD1775 (MK-1775) and Carboplatin to Treat p53 Mutated Refractory and Resistant Ovarian Cancer
Official title: Phase II Pharmacological Study With Wee-1 Inhibitor MK-1775 Combined With Carboplatin in Patients With p53 Mutated Epithelial Ovarian Cancer and Early Relapse (< 3 Months) or Progression During Standard First Line Treatment With an Additional Safety and Preliminary Anti-tumor Activity Cohort of Wee-1 Inhibitor AZD1775 Combined With Carboplatin in Patients With Platinum Resistant TP53 Mutated Epithelial Ovarian Cancer
Acronym: M10MKO
Sponsor: The Netherlands Cancer Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 24.0 (ACTUAL)
Number of arms: 1.0
Start date: 2010-07-31
Primary completion date: 2023-04-30
Completion date: 2023-04-30
Clinical trial NCT04731298: Study to Investigate the Pharmacokinetics, Pharmacodynamics and Assess the Efficacy and Safety to Support Dose Selection of Emapalumab in Pre-empting Graft Failure in Patients at High Risk After HSCT.
Official title: An Open Label, Single Arm, Multicentre, Proof of Concept, Phase 2 Study to Investigate the Pharmacokinetics, Pharmacodynamics and Assess the Efficacy and Safety to Support Dose Selection of Emapalumab in Pre-empting Graft Failure in Patients at High Risk After Allogeneic Hematopoietic Stem Cell Transplantation
Sponsor: Swedish Orphan Biovitrum (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Sponsor Decision related to Business Priorities, Assessment of Development Options
Enrollment: 2.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-05-25
Primary completion date: 2022-04-21
Completion date: 2022-04-21
Baseline population: No patients were enrolled in the emapalumab arm.
Limitations and caveats: The study was prematurely terminated with only 2 patients enrolled. Both patients were in the non-emapalumab treated arm, i.e. no patients received study treatment (emapalumab). Consequently, the majority of analyses were not performed and no conclusion on the efficacy of emapalumab on this patient population could be drawn from the study.
Clinical trial NCT03820908: Bisantrene for Relapsed /Refractory AML
Official title: Bisantrene for Relapsed /Refractory Acute Myelogenous Leukemia (AML)
Sponsor: Sheba Medical Center (OTHER_GOV)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 10.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-07-18
Primary completion date: 2020-05-19
Completion date: 2020-07-22
Clinical trial NCT03750552: Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure
Official title: A Phase 3, 4-week, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects With Primary Autonomic Failure
Acronym: SEQUOIA
Sponsor: Theravance Biopharma (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 195.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-01-24
Primary completion date: 2021-07-21
Completion date: 2021-07-21
Baseline population: The Baseline Analysis Population includes all participants from the Randomized Analysis Set.
Plan to share individual participant data: NO
IPD sharing description: Theravance Biopharma, Inc. will not be sharing individual de-identified participant data or other relevant study documents.
Clinical trial NCT03593655: Evaluating the Safety of and Adherence to a Vaginal Matrix Ring Containing Dapivirine and Oral Emtricitabine/Tenofovir Disoproxil Fumarate in an Adolescent and Young Adult Female Population
Official title: A Phase 2a Crossover Trial Evaluating the Safety of and Adherence to a Vaginal Matrix Ring Containing Dapivirine and Oral Emtricitabine/Tenofovir Disoproxil Fumarate in an Adolescent and Young Adult Female Population
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 247.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-01-14
Primary completion date: 2021-09-09
Completion date: 2021-09-09
Clinical trial NCT04860297: A Study to Evaluate Safety and Immunogenicity of mRNA-1273 Vaccine to Prevent COVID-19 in Adult Organ Transplant Recipients and in Healthy Adult Participants
Official title: A Phase 3b, Open-Label, Safety and Immunogenicity Study of SARS-CoV-2 mRNA-1273 Vaccine in Adult Solid Organ Transplant Recipients and Healthy Controls
Sponsor: ModernaTX, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 234.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-04-16
Primary completion date: 2023-05-22
Completion date: 2023-05-22
Baseline population: Safety set included all participants who received at least 1 dose of study drug in this study.
Limitations and caveats: Healthy participants cohort was included as a control group in the evaluation of humoral and cell-mediated immune response only; no comparisons of safety data with the healthy participants were made.
Plan to share individual participant data: NO
Clinical trial NCT02756130: Birinapant and Carboplatin in Treating Patients With Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Official title: A Phase I/II, Single Center, Proof-of-Concept Study of Birinapant in Combination With Platinum Based Chemotherapy Targeting Recurrent High Grade Serous Ovarian Carcinomas (HGSOC)
Sponsor: Jonsson Comprehensive Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: funding was not secured
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-08-01
Primary completion date: 2020-02-01
Completion date: 2021-02-01
Clinical trial NCT05375825: Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing Mesothelin
Official title: Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing Mesothelin
Sponsor: National Institutes of Health Clinical Center (CC) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: No participants enrolled.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2024-01-31
Primary completion date: 2024-01-31
Completion date: 2024-01-31
Plan to share individual participant data: YES
IPD sharing description: .All IPD recorded in the medical record will be shared with intramural investigators upon request.@@@@@@@@@@@@In addition, all large scale genomic sequencing data will be shared with subscribers to dbGaP.
IPD time frame: Clinical data available during the study and indefinitely. @@@@@@@@@@@@Genomic data are available once genomic data are uploaded per protocol GDS plan for as long as database is active.
IPD access criteria: Clinical data will be made available via subscription to BTRIS and with the permission of the study PI. @@@@@@@@@@@@Genomic data are made available via dbGaP through requests to the data custodians.
Clinical trial NCT03530683: A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma
Official title: A Phase 1a/1b Dose-Escalation and Expansion Trial of TTI-622 in Patients With Advanced Hematologic Malignancies, Including Lymphoma, Leukemia, and Multiple Myeloma
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: A business decision was made by Pfizer to terminate the study. Termination was not due to any safety concerns, requests from regulatory authorities, changes to the benefit/risk profile or any new concerns regarding the investigational product.
Enrollment: 189.0 (ACTUAL)
Number of arms: 7.0
Start date: 2018-05-14
Primary completion date: 2024-07-18
Completion date: 2024-07-18
Plan to share individual participant data: NO
IPD sharing description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Clinical trial NCT03420521: Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors
Official title: An Open-Label, Single Arm Phase II Study of Nivolumab in Combination With Ipilimumab in Subjects With Advanced Neuroendocrine Tumors
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Loss of funding
Enrollment: 9.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-03-09
Primary completion date: 2021-11-24
Completion date: 2021-11-24
Plan to share individual participant data: NO
Clinical trial NCT04666623: Compare the Efficacy and Safety of Intranasal Esketamine in Chronic Opioid Refractory Pain
Official title: IMPORTANCE Trial - A Provisional Study-design of a Single-center, Phase II, Double-blinded, Placebo-controlled, Randomized, 4-week Study to Compare the Efficacy and Safety of Intranasal Esketamine in Chronic Opioid Refractory Pain
Acronym: IMPORTANCE
Sponsor: University Hospital, Basel, Switzerland (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: investigator decision
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-11-25
Primary completion date: 2023-10-11
Completion date: 2023-10-11
Clinical trial NCT03126435: EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX
Official title: A Randomized Controlled, Open Label, Adaptive Phase-3 Trial to Evaluate Safety and Efficacy of EndoTAG-1+GEM vs GEM Alone in Patients With Measurable Locally Advanced/Metastatic Adenocarcinoma of the Pancreas Failed on FOLFIRINOX Treatment
Sponsor: SynCore Biotechnology Co., Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 218.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-10-16
Primary completion date: 2021-07-30
Completion date: 2021-10-08
Clinical trial NCT03685344: Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma
Official title: A Phase 1 Open-Label Study to Evaluate the Safety and Antitumor Activity of Loncastuximab Tesirine and Durvalumab in Patients With Advanced Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma
Sponsor: ADC Therapeutics S.A. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: In a limited number of patients, no additional activity was evident for the combination vs. loncastuximab tesirine monotherapy.
Enrollment: 13.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-02-04
Primary completion date: 2020-10-27
Completion date: 2020-10-27
Baseline population: Safety analysis set - All participants who received the study drug. The study was terminated during the dose escalation part of the study and the dose expansion part was not initiated, therefore data is only available for the dose escalation.
Plan to share individual participant data: NO
Clinical trial NCT03819660: Long Term Safety of Amifampridine Phosphate in Spinal Muscular Atrophy 3
Official title: Long Term Safety Study of Amifampridine Phosphate in Ambulatory Patients With Spinal Muscular Atrophy (SMA) Type 3
Acronym: SMA3
Sponsor: Catalyst Pharmaceuticals, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Development of indication not being pursued
Enrollment: 13.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-03-07
Primary completion date: 2021-09-13
Completion date: 2021-09-13
Limitations and caveats: The results of efficacy are limited to the assessment of quality of life using the INQoL. The premature interruption of the study determined that few patients had available data of INQoL from Month 6 onwards.
Plan to share individual participant data: NO
Clinical trial NCT03385928: STOP-MSU: Stopping Haemorrhage With Tranexamic Acid for Hyperacute Onset Presentation Including Mobile Stroke Units
Official title: STOP-MSU: Stopping Haemorrhage With Tranexamic Acid for Hyperacute Onset Presentation Including Mobile Stroke Units. A Phase II Randomised, Placebo-controlled, Investigator-driven Trial of Tranexamic Acid Within 2 Hours of Intracerebral Haemorrhage
Sponsor: Neuroscience Trials Australia (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 201.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-03-19
Primary completion date: 2023-05-28
Completion date: 2023-05-28
Clinical trial NCT03046927: Vitamin D and Residual Beta-Cell Function in Type 1 Diabetes
Official title: Vitamin D and Residual Beta-Cell Function in Type 1 Diabetes
Acronym: PCR
Sponsor: University of Massachusetts, Worcester (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: COMPLETED 
Enrollment: 48.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-10-19
Primary completion date: 2021-04-12
Completion date: 2021-04-20
Plan to share individual participant data: NO
IPD sharing description: No.